Company intelligence / Profile preview

PPC Group

Shanghai, China

Ownership: Private
Employees: ~600
Development stage: Other

Overview

PPC Group has enabled over 500 Phase I-IV clinical trials and 1500+ generic drug bioequivalence studies in Asia-Pacific; first CRO in region to pass inspections by US FDA, EU EMA, Japan PMDA, China NMPA; contributed to successful client product registrations.

Therapeutic areas: OncologyOther
Modalities: Small moleculeBiologicMonoclonal antibody
Industry: Contract Research Organization

Partnerships

Novotech Health Holdings

Beyond the preview

Go deeper on PPC Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PPC Group.

Explore the full profile